| langue originale | Anglais |
|---|---|
| Pages (de - à) | 1039-1041 |
| Nombre de pages | 3 |
| journal | Cancer Cell |
| Volume | 39 |
| Numéro de publication | 8 |
| Les DOIs | |
| état | Publié - 9 août 2021 |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: Cancer Cell, Vol 39, Numéro 8, 09.08.2021, p. 1039-1041.
Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs
TY - JOUR
T1 - Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic
AU - Bayle, Arnaud
AU - Baldini, Capucine
AU - Martin-Romano, Patricia
AU - Michot, Jean Marie
AU - Champiat, Stéphane
AU - Bahleda, Rastilav
AU - Gazzah, Anas
AU - Marabelle, Aurélien
AU - Verlingue, Loic
AU - Geraud, Arthur
AU - Morel, Daphné
AU - Michiels, Stefan
AU - Hollebecque, Antoine
AU - Albiges, Laurence
AU - Besse, Benjamin
AU - Soria, Jean Charles
AU - Massard, Christophe
AU - Barlesi, Fabrice
AU - Postel-Vinay, Sophie
N1 - Funding Information: As part of the Drug Development Department (DITEP), A.B., C.B., P.M.-R., J.-M.M., S.C., R.B., A. Gazzah, A.M., L.V., A. Geraud, A.H., C.M., and S.P.-V. report the following: Principal/sub-Investigator of Clinical Trials for Abbvie, Adaptimmune, Adlai Nortye USA Inc., Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Astex Pharmaceuticals, Astra Zeneca Ab, Aveo, Basilea Pharmaceutica International Ltd., Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, BicycleTx Ltd, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Curevac, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd., Forma Tharapeutics, Gamamabs, Genentech, Glaxosmithkline, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Turning Point Therapeutics, and Xencor; research grants from Astrazeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, and Sanofi; and non-financial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, GSK, Medimmune, Merck, NH TherAGuiX, Pfizer, and Roche. J.-M.M. reports other support from Astra-Zeneca, Bristol-Myers Squibb, Boehringer–Ingelheim, Eli Lilly Oncology, β. Hoffmann–La Roche Ltd, Merck, MSD, Pfizer, Regeneron, outside this work. Over the last 5 years, A.M. has been a Principal Investigator of Clinical Trials from the following companies: Roche/Genentech, BMS, Merck (MSD), Pfizer, Lytix pharma, Eisai, Astra Zeneca/Medimmune, Tesaro, Chugai, OSE immunotherapeutics, SOTIO, Molecular Partners, IMCheck, Pierre Fabre, and Adlai Nortye. A.M. has been a Member of Clinical Trial Steering Committees for NCT02528357 (GSK), NCT03334617 (AZ) and a Member of Data Safety and Monitoring Board: NCT02423863 (Sponsor: Oncovir), NCT03818685 (Sponsor: Centre Léon Bérard). A.M. has been a compensated member of the following Scientific Advisory Boards: Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Medicxi, HiFiBio, IMCheck, MSD, iTeos, Innate Pharma, Shattuck Labs, Medincell, Tessa Therapeutics, and Deka Biosciences. A.M. has provided compensated Teaching/Speaker activities for Roche/Genentech, BMS, Merck (MSD), Merck Serono, Astra Zeneca/Medimmune, Amgen, Sanofi, and Servier. A.M. has provided compensated Scientific & Medical Consulting for Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi/BioNTech, Molecular Partners, Pillar Partners, BPI, Faron, and Applied Materials. A.M. has benefited of Non-Financial Support (travel expenses) from Astra Zeneca, BMS, Merck (MSD), and Roche. AM is a shareholder of Pegascy SAS, Centessa Pharmaceuticals, HiFiBio, and Shattuck Labs. A.M. has received pre-clinical and clinical research grants (Institutional Funding) from Merus, BMS, Boehringer Ingelheim, Transgene, Fondation MSD Avenir, Sanofi and Astra Zeneca. L.V. reports personal fees from Adaptherapy, non-personal fees from Pierre-Fabre and Servier, and grants from Bristol-Myers Squibb, all outside this work. S.M. reports fees outside this work from statistical advice (IDDI, Amaris, Roche) and from data and safety monitoring membership of clinical trials (Sensorion, Biophytis, Servier, Yuhan). A.H. reports personal fees from Amgen, BMS, Debiopharm, EISAI, and QED Therapeutics, non-financial support from Lilly, personal fees and non-financial support from Incyte, and other from Astra-Zeneca, Roche, Servier, outside this work. L.A. reports honoraria (Institution) advisory/consultancy: Astellas, Astrazeneca, Bellerophon, BMS, Corvus Pharmaceuticals, Ipsen, Janssen, Merck & Co, MSD, Novartis, Pfizer, Springer Healthcare; Research Grant/Funding (Institution): BMS. B.B. reports sponsored research at Gustave Roussy Cancer Center from 4D Pharma, Abbvie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Inivata, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, and Tolero Pharmaceuticals. J.-C. S. reports serving as a full-time employee of Medimmune/Astra Zeneca from September 2017 to December 2019; receiving consultancy fees from Astra Zeneca, Astex, Bayer, Blend Therapeutics, Boehringer-Ingelheim, Clovis, GamaMabs, Lilly, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche-Genentech, Sanofi, Servier, Symphogen and Tarveda and serving as a shareholder of Gritstone. C.M. reports consultant/advisory fees from Amgen, Astellas, Astra Zeneca,Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, and Orion. F.B. reports personal fees from Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eli Lilly Oncology,β. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and Takeda, outside this work. S. P.-V. reports research grants (institutional) from AstraZeneca, Roche and Boehringher Ingelheim. Funding Information: As part of the Drug Development Department (DITEP), A.B. C.B. P.M.-R. J.-M.M. S.C. R.B. A. Gazzah, A.M. L.V. A. Geraud, A.H. C.M. and S.P.-V. report the following: Principal/sub-Investigator of Clinical Trials for Abbvie, Adaptimmune, Adlai Nortye USA Inc. Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Astex Pharmaceuticals, Astra Zeneca Ab, Aveo, Basilea Pharmaceutica International Ltd. Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, BicycleTx Ltd, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Curevac, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd. Forma Tharapeutics, Gamamabs, Genentech, Glaxosmithkline, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Turning Point Therapeutics, and Xencor; research grants from Astrazeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, and Sanofi; and non-financial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, GSK, Medimmune, Merck, NH TherAGuiX, Pfizer, and Roche. J.-M.M. reports other support from Astra-Zeneca, Bristol-Myers Squibb, Boehringer–Ingelheim, Eli Lilly Oncology, β. Hoffmann–La Roche Ltd, Merck, MSD, Pfizer, Regeneron, outside this work. Over the last 5 years, A.M. has been a Principal Investigator of Clinical Trials from the following companies: Roche/Genentech, BMS, Merck (MSD), Pfizer, Lytix pharma, Eisai, Astra Zeneca/Medimmune, Tesaro, Chugai, OSE immunotherapeutics, SOTIO, Molecular Partners, IMCheck, Pierre Fabre, and Adlai Nortye. A.M. has been a Member of Clinical Trial Steering Committees for NCT02528357 (GSK), NCT03334617 (AZ) and a Member of Data Safety and Monitoring Board: NCT02423863 (Sponsor: Oncovir), NCT03818685 (Sponsor: Centre Léon Bérard). A.M. has been a compensated member of the following Scientific Advisory Boards: Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Medicxi, HiFiBio, IMCheck, MSD, iTeos, Innate Pharma, Shattuck Labs, Medincell, Tessa Therapeutics, and Deka Biosciences. A.M. has provided compensated Teaching/Speaker activities for Roche/Genentech, BMS, Merck (MSD), Merck Serono, Astra Zeneca/Medimmune, Amgen, Sanofi, and Servier. A.M. has provided compensated Scientific & Medical Consulting for Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi/BioNTech, Molecular Partners, Pillar Partners, BPI, Faron, and Applied Materials. A.M. has benefited of Non-Financial Support (travel expenses) from Astra Zeneca, BMS, Merck (MSD), and Roche. AM is a shareholder of Pegascy SAS, Centessa Pharmaceuticals, HiFiBio, and Shattuck Labs. A.M. has received pre-clinical and clinical research grants (Institutional Funding) from Merus, BMS, Boehringer Ingelheim, Transgene, Fondation MSD Avenir, Sanofi and Astra Zeneca. L.V. reports personal fees from Adaptherapy, non-personal fees from Pierre-Fabre and Servier, and grants from Bristol-Myers Squibb, all outside this work. S.M. reports fees outside this work from statistical advice (IDDI, Amaris, Roche) and from data and safety monitoring membership of clinical trials (Sensorion, Biophytis, Servier, Yuhan). A.H. reports personal fees from Amgen, BMS, Debiopharm, EISAI, and QED Therapeutics, non-financial support from Lilly, personal fees and non-financial support from Incyte, and other from Astra-Zeneca, Roche, Servier, outside this work. L.A. reports honoraria (Institution) advisory/consultancy: Astellas, Astrazeneca, Bellerophon, BMS, Corvus Pharmaceuticals, Ipsen, Janssen, Merck & Co, MSD, Novartis, Pfizer, Springer Healthcare; Research Grant/Funding (Institution): BMS. B.B. reports sponsored research at Gustave Roussy Cancer Center from 4D Pharma, Abbvie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cergentis, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, GSK, Inivata, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, and Tolero Pharmaceuticals. J.-C. S. reports serving as a full-time employee of Medimmune/Astra Zeneca from September 2017 to December 2019; receiving consultancy fees from Astra Zeneca, Astex, Bayer, Blend Therapeutics, Boehringer-Ingelheim, Clovis, GamaMabs, Lilly, Mission Therapeutics, Merus, Pfizer, PharmaMar, Pierre Fabre, Roche-Genentech, Sanofi, Servier, Symphogen and Tarveda and serving as a shareholder of Gritstone. C.M. reports consultant/advisory fees from Amgen, Astellas, Astra Zeneca,Bayer, BeiGene, BMS, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, MSD, Novartis, Pfizer, Roche, Sanofi, and Orion. F.B. reports personal fees from Astra-Zeneca, Bayer, Bristol-Myers Squibb, Boehringer–Ingelheim, Eli Lilly Oncology,β. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and Takeda, outside this work. S. P.-V. reports research grants (institutional) from AstraZeneca, Roche and Boehringher Ingelheim.
PY - 2021/8/9
Y1 - 2021/8/9
UR - http://www.scopus.com/inward/record.url?scp=85109462289&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2021.06.010
DO - 10.1016/j.ccell.2021.06.010
M3 - Letter
C2 - 34197735
AN - SCOPUS:85109462289
SN - 1535-6108
VL - 39
SP - 1039
EP - 1041
JO - Cancer Cell
JF - Cancer Cell
IS - 8
ER -